Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib With or Without Osimertinib in Metastatic EGFR-Mutant Lung Cancer
NCT03755102Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2018
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dacomitinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 1 year. Started Nov 2018; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03755102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755102.